Octreotide News and Research RSS Feed - Octreotide News and Research

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer. [More]
Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours. [More]
Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today announced that it has entered a collaboration with German biotechnology company Cilian AG to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, CiFlu, for delivery using Glide's patient-friendly SDI delivery device. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo). [More]
Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo). [More]
Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism. [More]
Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV [More]
Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Ectopic tumours secreting corticotropin-releasing hormone and adrenocorticotropic hormone are very rare in children and can result in a misdiagnosis of Cushing’s disease, say researchers. [More]
Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later. [More]
Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy. [More]
Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. [More]
FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. [More]
Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours. [More]
FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention. [More]
Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. [More]
Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. [More]
Advertisement
Advertisement